Suzhou Pharmaceutical Technology

Pharmidia (Suzhou Pharmidia Pharmaceutical Technology) is a clinical-stage biopharmaceutical company based in Suzhou, China, focused on the discovery and development of innovative small molecule therapeutics for oncology and metabolic diseases. The company's lead program, FMD-011, is a potent Pan-RAF inhibitor currently being evaluated in Phase 1/2 clinical trials for the treatment of advanced solid tumors, including those with BRAF or NRAS mutations. Pharmidia's pipeline also features FMD-021, an ACC inhibitor for non-alcoholic steatohepatitis (NASH), and FMD-031, a URAT1 inhibitor for the treatment of gout. Backed by prominent investors such as Lilly Asia Ventures and Matrix Partners China, Pharmidia leverages its R&D center in the Suzhou Biobay to address significant unmet medical needs through precision medicine.